fbpx

Ranbaxy TPP Generic Nexium, Diovan, and Valcyte Settlement

Sun Pharmaceutical Industries, Ltd. and Ranbaxy, Inc. are settling combined class actions alleging generic drug manufacturer Ranbaxy made misrepresentations about both the conditions in its plants and the results of analyses on the integrity of data at the plants. This allowed it to obtain “tentative approval” from the Food and Drug Administration (FDA) and a  Read more

Sun Pharmaceuticals Sign at Building

Opioid Epidemic Costs to Florida Public Schools RICO Class Action

This class action brings suit against a long list of pharmaceutical manufacturers and distributors of opioids, on behalf of independent public school districts in Florida. The complaint claims, “public schools have been shouldering perhaps the most profound and enduring consequences of the nationwide opioid epidemic.” It points to schools’ needs to provide special education and  Read more

Colorful Pills on Blue Surface

Avanir Encouraged Nuedexta Use for Off-Label Purposes Class Action

When drugs are approved by the Food and Drug Administration (FDA), they are approved for specific uses, to treat specific diseases or problems. The complaint for this class action brings suit against Avanir Pharmaceuticals, Inc., which it claims attempted to market a drug called Nuedexta for other than its original uses, including, it claims, by  Read more

Red Pills Resembling Nuedexta

Grand Canyon University Accreditation Standards Class Action

This class action sues a for-profit university, Grand Canyon University, Inc., and related parties, about their online graduate programs. The school offers graduate degrees in areas that are subject to state regulation, but the complaint for this class action alleges that the programs do not meet the accreditation standards for many state licensing boards and  Read more

Grand Canyon University Campus

Mylan Antitrust EpiPen Settlement

A group of entities—including Mylan NV, Mylan Specialty LP, Mylan Pharmaceuticals, Inc., Viatris, Inc., and Heather Bresch—has agreed to pay $246 million to settle class actions alleging that they violated antitrust, federal racketeering, and other laws, preventing effective competition and causing consumers and insurers to pay too much for EpiPen products. The products at issue  Read more

Close-Up of Two EpiPens

Regeneron “Charity” Boosted Sales of More Expensive Drug Class Action

Regeneron Pharmaceuticals, Inc. makes the drug Eylea, which is a prescription injection designed to treat wet age-related macular degeneration (wet AMD), an eye disease that can lead to blindness. Eylea is more expensive than the competing drug Avastin, but the complaint for this class action alleges that Regeneron used an illegal scheme involving a purported  Read more

Regeneron Eylea

Itria, Biz2Credit “Future Receivables Purchases” RICO Class Action

This class action involves financing provided to businesses by Itria Ventures, LLC and Biz2Credit, Inc. The complaint alleges that the companies offer “future receivables purchases” rather than loans, but that they renege on terms of the financing, charge usurious interest rates, and engage in racketeering.  Read more

Gavel in Front of Books

Viatris and Mylan Epinephine Antitrust and RICO Violations Virginia Class Action

The complaint for this class action opens with the words, “This case presents one of the most egregious examples of corporate greed and malfeasance in our nation’s history.” It alleges that the companies behind EpiPens have violated antitrust laws and the Racketeer Influenced and Corrupt Organizations (RICO) Act to maintain a monopoly on the epinephrine  Read more

Close-Up of Two EpiPens

CITIC Capital RICO Conspiracy GNC Shareholders’ Class Action

This class action is brought by minority shareholders in GNC Holdings, Inc. The complaint alleges that “a number of state-owned Chinese corporations and individuals, GNC’s Board of Directors and senior management, certain [of] GNC’s secured lenders and financial advisor” who have conspired “to enrich themselves at the expense” of other shareholders through dishonest actions that  Read more

Sign at GNC World Headquarters

EpiPen Antitrust and RICO Settlement

A partial settlement has been reached in a consolidated class action concerning the marketing and sales of EpiPens, with Pfizer, Inc., Meridian Medical Technologies, Inc., and King Pharmaceuticals, LLC. The complaint alleged the companies violated state antitrust laws and the federal Racketeering and Corrupt Organizations (RICO) Act, harming competition and causing consumers to overpay for  Read more

Close-Up of Two EpiPens